Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ATRX Held at DTC
12,514,718
05/02/2022
$ATRX Outstanding Shares
17,493,237
05/02/2022
$ATRX Outstanding Shares
17,493,237
05/02/2022
$ATRX Authorized Shares
180,000,000
05/02/2022
$ATRX Authorized Shares
180,000,000
05/02/2022
$ATRX Market Cap 1,111,695
05/20/2022
$ATRX Market Cap 1,111,695
05/20/2022
$ATRX In addition to advancing both drug candidates in Phase 2 clinical trials, the Company remains active in exploring other advanced drug development opportunities while maintaining its legacy assets, including CEQ508, an oral delivery of small interfering RNA (siRNA) against beta-catenin, to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis (FAP).
$ATRX In addition to advancing both drug candidates in Phase 2 clinical trials, the Company remains active in exploring other advanced drug development opportunities while maintaining its legacy assets, including CEQ508, an oral delivery of small interfering RNA (siRNA) against beta-catenin, to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis (FAP).
$ATRX MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease (PD) and represents the only drug to address both movement and non-movement symptoms of PD. Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications.
$ATRX MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease (PD) and represents the only drug to address both movement and non-movement symptoms of PD. Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications.
$ATRX Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies.
$ATRX Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies.
$ATRX The Company has recently licensed two drug candidates, MLR-1019 and MLR-1023, from the Melior Discovery family of companies.
$ATRX The Company has recently licensed two drug candidates, MLR-1019 and MLR-1023, from the Melior Discovery family of companies.
$ATRX Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.
$ATRX Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.
$ATRX Beneficial Shareholder 1,339 09/30/2021
$ATRX Beneficial Shareholder 1,339 09/30/2021
$ATRX Float 13,530,709
08/31/2021
$ATRX Float 13,530,709
08/31/2021
$ATRX Held at DTC
12,514,718 05/02/2022
$ATRX Held at DTC
12,514,718 05/02/2022
$ATRX Outstanding Shares
17,493,237 05/02/2022
$ATRX Outstanding Shares
17,493,237 05/02/2022
$ATRX Authorized Shares
180,000,000
05/02/2022
$ATRX Authorized Shares
180,000,000
05/02/2022
$NNRX In 2021, The Plant generated $1.7 million in revenue operating from temporary facilities while the new building was under construction. During the first quarter of 2022, manufacturing was transitioned into the new facility, and the Q1 revenue run rate expanded to $879k (approximately $3.5 million on an annualized basis). The overall forecast for 2022 is $15 million in total top line sales, making the company cash flow positive through expanded product lines, including beverage powders, tablets, infused pre-rolls and concentrates. All necessary licensing is already in place for manufacturing, distribution, and sales of these new product lines.
Bishop added, "The Plant represents a vertically integrated operation with tremendous scalability. We look forward to providing more details in the very near future."
$NNRX In 2021, The Plant generated $1.7 million in revenue operating from temporary facilities while the new building was under construction. During the first quarter of 2022, manufacturing was transitioned into the new facility, and the Q1 revenue run rate expanded to $879k (approximately $3.5 million on an annualized basis). The overall forecast for 2022 is $15 million in total top line sales, making the company cash flow positive through expanded product lines, including beverage powders, tablets, infused pre-rolls and concentrates. All necessary licensing is already in place for manufacturing, distribution, and sales of these new product lines.
Bishop added, "The Plant represents a vertically integrated operation with tremendous scalability. We look forward to providing more details in the very near future."
$NNRX The Company's acquisition of The Plant includes the lease of a 30,000 square foot manufacturing and 28,000 square foot cultivation facility. In addition, NutraNomics has also already acquired over $2 million in related specialized equipment and continues to invest in productive hard assets for expanded operations involving extraction, production, and materials.
$NNRX The Company's acquisition of The Plant includes the lease of a 30,000 square foot manufacturing and 28,000 square foot cultivation facility. In addition, NutraNomics has also already acquired over $2 million in related specialized equipment and continues to invest in productive hard assets for expanded operations involving extraction, production, and materials.
$NNRX NutraNomics, Inc. (OTC PINK:NNRX) ("NutraNomics" or the "Company"), an emerging leader in organic plant-based nutritional science and innovation, is pleased to announce its 100% acquisition of DHS Development, Inc. (d/b/a "The Plant"), and Affiliates.
"This transaction positions the Company for significant upside potential as an emerging leader in the vertically integrated cannabis products space," commented Jonathan Bishop, CEO of NutraNomics.
$NNRX NutraNomics, Inc. (OTC PINK:NNRX) ("NutraNomics" or the "Company"), an emerging leader in organic plant-based nutritional science and innovation, is pleased to announce its 100% acquisition of DHS Development, Inc. (d/b/a "The Plant"), and Affiliates.
"This transaction positions the Company for significant upside potential as an emerging leader in the vertically integrated cannabis products space," commented Jonathan Bishop, CEO of NutraNomics.
$FBCD FBC Holding, Inc. (OTC PINK:FBCD) through its wholly owned subsidiary, Formrunner Apparel Inc. is pleased to announce that the company may be acquiring a 3rd retail location at Fashion Show Mall in Las Vegas.
FBC Holding, Inc. is currently getting an application reviewed for a retail location at Fashion Show in Las Vegas. Fashion Show is a shopping mall located on the Las Vegas Strip in Paradise, Nevada. The mall hosts weekend fashion shows on a retractable runway within the mall's central atrium, hence the name. Once location is approved, this is going to be huge and will open many avenues along with growth and massive revenue opportunities.
$ATRX The Company has licensed two drug candidates, MLR-1019 and MLR-1023, from the Melior Discovery family of companies. Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients. Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies. MLR-1019 (armesocarb) is a new class of drug for Parkinson’s Disease (PD) and is believed by the Company to represents the only drug to address both movement and non-movement symptoms of PD. Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications. In addition to advancing both drug candidates in Phase 2 clinical trials, the Company remains active in exploring other advanced drug development opportunities while maintaining its legacy assets, including CEQ508, an oral delivery of small interfering RNA (siRNA) against beta-catenin, to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis (FAP).
$ATRX The Company has licensed two drug candidates, MLR-1019 and MLR-1023, from the Melior Discovery family of companies. Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients. Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies. MLR-1019 (armesocarb) is a new class of drug for Parkinson’s Disease (PD) and is believed by the Company to represents the only drug to address both movement and non-movement symptoms of PD. Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications. In addition to advancing both drug candidates in Phase 2 clinical trials, the Company remains active in exploring other advanced drug development opportunities while maintaining its legacy assets, including CEQ508, an oral delivery of small interfering RNA (siRNA) against beta-catenin, to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis (FAP).
$ATRX Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.
$ATRX Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.
$ATRX Dr. Buteau’s groundbreaking work has earned him numerous accolades and funding awards supporting additional laboratory and clinical research. These include, but are not limited to, grants from the Alberta Diabetes Institute, DRIFCan, Defeating Diabetes, Shastri Indo-Canada Institute, Canada Foundation for Innovation, Canadian Institutes of Health Research, and Natural Science and Engineering Research Council.
Interested parties are strongly encouraged to view two short videos from November 2020 and June 2021 highlighting the potential of MLR-1023 and the accomplishments of Dr. Buteau and his lab in the field of diabetes at:
$ATRX Dr. Buteau’s groundbreaking work has earned him numerous accolades and funding awards supporting additional laboratory and clinical research. These include, but are not limited to, grants from the Alberta Diabetes Institute, DRIFCan, Defeating Diabetes, Shastri Indo-Canada Institute, Canada Foundation for Innovation, Canadian Institutes of Health Research, and Natural Science and Engineering Research Council.
Interested parties are strongly encouraged to view two short videos from November 2020 and June 2021 highlighting the potential of MLR-1023 and the accomplishments of Dr. Buteau and his lab in the field of diabetes at: